Organometallic metal (arene) anticancer agents were believed to confer low selectivity for
potential cellular targets. However, the ruthenium (arene) pyridinecarbothioamide (plecstatin …

Organometallic metal (arene) anticancer agents require ligand exchange for their anticancer
activity and this is generally believed to confer low selectivity for potential cellular targets …

Activation kinetics of metallo-prodrugs control the types of possible interactions with
biomolecules. The intact metallo-prodrug is able to engage with potential targets by purely …

The ruthenium complex sodium trans-[tetrachloridobis (1 H-indazole) ruthenate
(iii)](KP1339/IT-139) showed preclinical activity in a variety of in vivo tumor models including …

Background Melanoma is a malignant tumor characterized by high proliferation and
aggressive metastasis. To address the molecular mechanisms of the proto-oncogene, Rous …

Gemcitabine (GEM), as a first‐line chemotherapeutics for pancreatic ductal adenocarcinoma
(PDAC) treatment, still faces several clinical challenges, restricted by instability in blood …

The cytolinker and scaffolding protein, plectin, has emerged as a potent driver of malignant
hallmarks in many human cancers due to its involvement in various cellular activities …

We recently demonstrated that plectin is a robust biomarker for pancreatic ductal
adenocarcinoma (PDAC), one of the most aggressive malignancies. In normal physiology …

Plectin, as a cytoskeleton-related protein, is involved in various physiological and
pathological processes of many cell types. Studies have found that plectin affects cancer cell …

Background Plectin is one of the cytolinker proteins that play a crucial role in maintaining the
integrity of cellular architecture. It is a component of desmosome complexes connecting …